List view / Grid view
11 September 2014 | By Oxford Global Conferences
Oxford Global Conferences are proud to present the Drug Discovery USA Congress, taking place on 21 – 22 October at the Hyatt Boston Harbor Hotel, Boston, USA...
11 September 2014 | By Waters
Waters Corporation (NYSE: WAT) today celebrated the official opening of its new, custom-built mass spectrometry headquarters in Wilmslow, UK, confirming the company's commitment to innovation and the expanded usage of mass spectrometry...
11 September 2014 | By Ario Pharma
New chemistry strengthens Ario Pharma’s existing TRPA1 asthma programme and reduces time to selection of new drug candidates...
11 September 2014 | By DPT Laboratories
DPT Laboratories, a contract development and manufacturing organization (CDMO) with a specialized focus on semi-solid and liquid dosage forms, announces the acquisition of Meda Pharmaceuticals’ Lakewood, New Jersey, facilities...
27 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with MSD’s investigational anti-PD-1 antibody pembrolizumab...
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
12 August 2014 | By Sanofi
Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes...
11 August 2014 | By B3C newswire
FAAH Pharma Inc., announced an investment by TVM Life Science Ventures VII investment into the company.
7 August 2014 | By Daiichi Sankyo
...to develop and commercialize novel, fixed-dose combination hydrocodone products for pain and opioid-induced nausea and vomiting in the US.
6 August 2014 | By Yabao Pharmaceutical Co, Inc
Yabao Pharmaceutical Co, Inc. announced a strategic partnership with Changzhou Le Sun Pharmaceuticals Ltd.to co-develop Le Sun's leading PLK/PI3K dual inhibitor LS-008, which currently is under pre-clinical development...
5 August 2014 | By Roche
Roche announced that it has agreed to acquire Santaris Pharma, a privately held biopharmaceutical company based near Copenhagen, Denmark...
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...
4 August 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab, also known as ACTEMRA) has received a positive opinion from the Committee for Medicinal Products for Human Use for use in Europe...
